Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
$2.56
-3.8%
$3.83
$2.28
$44.88
$7.27M4.8764,734 shs41,417 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.30
-3.8%
$3.99
$2.70
$9.87
$8.56M2.2830,909 shs21,219 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.27
$1.29
$0.75
$7.44
$7.89M-1.052,742 shs1,804 shs
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$2.63
$3.81
$2.37
$48.79
$7.84M8.03332,331 shs14,931 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
-3.76%-4.83%-33.85%-56.97%-91.29%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-3.80%-3.15%+11.69%+41.91%-49.29%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%+1.08%-7.97%+48.10%-73.53%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
0.00%+1.54%-12.62%-57.10%-67.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
$1.26M5.77N/AN/A$18.99 per share0.13
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.45N/AN/A$13.18 per share0.33
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$67.60M0.12N/AN/A($9.01) per share-0.14
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$13.80M0.57N/AN/A$0.22 per share11.95

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
-$10.63M-$106.15N/AN/AN/A-544.63%-266.16%-96.52%5/9/2024 (Estimated)
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/8/2024 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%N/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$13.58M-$11.05N/AN/A-98.42%-665.17%-122.48%6/13/2024 (Estimated)

Latest NURO, INBS, VAPO, and VVOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A-$3.05-$3.05-$3.05N/A$3.25 million    
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million
2/9/2024Q2 2024
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
-$3.24-$2.07+$1.17-$2.07N/A$0.76 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
0.07
0.57
0.39
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.34
0.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
32.97%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
0.28%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
9.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Intelligent Bio Solutions Inc. stock logo
INBS
Intelligent Bio Solutions
512.84 million2.84 millionNot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.21 million5.23 millionNo Data
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1142.98 million2.70 millionOptionable

NURO, INBS, VAPO, and VVOS Headlines

SourceHeadline
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
proactiveinvestors.com - April 11 at 3:32 PM
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
finance.yahoo.com - April 9 at 6:42 PM
Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices
markets.businessinsider.com - April 9 at 1:41 PM
Whats Going On With Vivos Therapeutics Stock?What's Going On With Vivos Therapeutics Stock?
msn.com - April 9 at 1:41 PM
Medicare to reimburse for Vivos CARE sleep apnea devicesMedicare to reimburse for Vivos CARE sleep apnea devices
msn.com - April 9 at 1:41 PM
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursementVivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
proactiveinvestors.com - April 9 at 9:31 AM
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
investorplace.com - April 9 at 8:53 AM
Vivos Therapeutics files to sell 1.73M shares of common stock for holdersVivos Therapeutics files to sell 1.73M shares of common stock for holders
msn.com - April 9 at 8:41 AM
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
finance.yahoo.com - April 9 at 8:41 AM
Vivos Therapeutics Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
globenewswire.com - April 9 at 7:30 AM
Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety ReportVerve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report
precisionmedicineonline.com - April 2 at 5:52 PM
Vivos Therapeutics highlights path to cash flow positivity after FDA clearanceVivos Therapeutics highlights path to cash flow positivity after FDA clearance
proactiveinvestors.com - April 1 at 9:07 AM
Vivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsVivos Therapeutics Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 31 at 1:42 PM
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 12:38 PM
Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss
marketwatch.com - March 29 at 1:13 AM
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
globenewswire.com - March 28 at 4:05 PM
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
globenewswire.com - March 28 at 7:30 AM
Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report
benzinga.com - February 22 at 12:09 PM
Vivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesVivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades
benzinga.com - February 22 at 7:09 AM
Vivos Therapeutics secures $4 million through warrant exerciseVivos Therapeutics secures $4 million through warrant exercise
investing.com - February 18 at 12:39 AM
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
finance.yahoo.com - February 15 at 9:27 AM
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrantVivos Therapeutics sees gross proceeds of $4M from exercise of warrant
proactiveinvestors.com - February 15 at 9:13 AM
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
finance.yahoo.com - February 12 at 9:45 AM
Vivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
finanznachrichten.de - February 6 at 10:18 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Intelligent Bio Solutions logo

Intelligent Bio Solutions

NASDAQ:INBS
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Vivos Therapeutics logo

Vivos Therapeutics

NASDAQ:VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.